SRZN

Company Overview — What Does Surrozen, Inc./DE Do?

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California. Surrozen, Inc./DE (SRZN) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Craig C. Parker and employs approximately 80 people. With a market capitalization of $335M, SRZN is one of the notable companies in the Healthcare sector.

Surrozen, Inc./DE (SRZN) Stock Rating — Hold (April 2026)

As of April 2026, Surrozen, Inc./DE receives a Hold rating with a composite score of 35.5/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.SRZN ranks #1,864 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Surrozen, Inc./DE ranks #191 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SRZN Stock Price and 52-Week Range

Surrozen, Inc./DE (SRZN) currently trades at $28.20. The stock gained $0.75 (2.7%) in the most recent trading session. The 52-week high for SRZN is $29.59, which means the stock is currently trading -4.7% from its annual peak. The 52-week low is $5.90, putting the stock 378.0% above its annual trough. Recent trading volume was 216K shares, suggesting relatively thin trading activity.

Is SRZN Overvalued or Undervalued? — Valuation Analysis

Surrozen, Inc./DE (SRZN) carries a value factor score of 20/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 22.86x, compared to 1.66x for the average Healthcare stock.

At current multiples, Surrozen, Inc./DE trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Surrozen, Inc./DE Profitability — ROE, Margins, and Quality Score

Surrozen, Inc./DE (SRZN) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 1202.4%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at -61.1% versus the sector average of -33.1%.

On a margin basis, Surrozen, Inc./DE reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -746.0% (sector: -66.1%). Net profit margin stands at -1500.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -90.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SRZN Debt, Balance Sheet, and Financial Health

Surrozen, Inc./DE has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 9.22x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $81M.

SRZN has a beta of 0.57, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Surrozen, Inc./DE is 46/100, reflecting average volatility within the normal range for its sector.

Surrozen, Inc./DE Revenue and Earnings History — Quarterly Trend

In TTM 2026, Surrozen, Inc./DE reported revenue of $13M and earnings per share (EPS) of $-32.37. Net income for the quarter was $-60M. Gross margin was 100.0%. Operating income came in at $-28M.

In FY 2025, Surrozen, Inc./DE reported revenue of $3M and earnings per share (EPS) of $-32.37. Net income for the quarter was $-242M. Revenue grew -67.4% year-over-year compared to FY 2024. Operating income came in at $-42M.

In Q3 2025, Surrozen, Inc./DE reported revenue of $983,000 and earnings per share (EPS) of $-8.36. Net income for the quarter was $-72M. Revenue grew -90.2% year-over-year compared to Q3 2024. Operating income came in at $-11M.

In Q2 2025, Surrozen, Inc./DE reported revenue of $983,000 and earnings per share (EPS) of $2.55. Net income for the quarter was $40M. Operating income came in at $-9M.

Over the past 8 quarters, Surrozen, Inc./DE has demonstrated a growth trajectory, with revenue expanding from $0 to $13M. Investors analyzing SRZN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SRZN Dividend Yield and Income Analysis

Surrozen, Inc./DE (SRZN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SRZN Momentum and Technical Analysis Profile

Surrozen, Inc./DE (SRZN) has a momentum factor score of 73/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 21/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

SRZN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Surrozen, Inc./DE (SRZN) ranks #191 out of 838 stocks based on the Blank Capital composite score. This places SRZN in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SRZN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SRZN vs S&P 500 (SPY) comparison to assess how Surrozen, Inc./DE stacks up against the broader market across all factor dimensions.

SRZN Next Earnings Date

No upcoming earnings date has been announced for Surrozen, Inc./DE (SRZN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SRZN? — Investment Thesis Summary

Surrozen, Inc./DE presents a balanced picture with arguments on both sides. The quality score of 16/100 flags below-average profitability. The value score of 20/100 indicates premium valuation. Price momentum is positive at 73/100, suggesting the trend favors buyers.

In summary, Surrozen, Inc./DE (SRZN) earns a Hold rating with a composite score of 35.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SRZN stock.

Related Resources for SRZN Investors

Explore more research and tools: SRZN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SRZN head-to-head with peers: SRZN vs AZN, SRZN vs SLGL, SRZN vs VMD.